SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

There's a lot of exciting therapies that have emerged over the last 10 years and there's more therapies coming down the ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program.

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...